Ben Bergo, CEO of Visus, shares data from the company's pivotal phase 3 BRIO-1 trial, as well as answers questions about Brimochol PF.
Ben Bergo
Advertisement
Articles by Ben Bergo
Advertisement
Latest Updated Articles
VEW 2023: Phase 3 BRIO-I data for brimochol PF for presbyopiaSeptember 29th 2023
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Takeaways from this week in optometry: July 27- July 31
2
CLI study: Contact lens patients significantly more profitable than spectacle-only wearers
3
Back to school season provides practice growth opportunities
4
PROSE treatment improves Mackie stage in neurotrophic keratitis in study
5